The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19)
has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical …

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide …

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant of concern Omicron (B. 1.1. 529) has a large number of mutations, especially in the …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …

Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

Abstract BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve
around the world, generating new variants that are of concern on the basis of their potential …

Abstract Severe Acute Respiratory Coronavirus (SARS-CoV-2) has been emerging in the
form of different variants since its first emergence in early December 2019. A new Variant of …